Could a common diabetes drug stop prediabetes in its tracks?
NCT ID NCT06828731
First seen Nov 28, 2025 · Last updated Jun 21, 2026 · Updated 28 times
Summary
This study tested whether the diabetes drug empagliflozin can be used in people with prediabetes to help prevent the condition from progressing to full-blown diabetes. Sixty veterans with prediabetes took either empagliflozin or received standard lifestyle advice for 12 weeks. The main goal was to see if such a study is even possible to run, not yet to prove the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREDIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charles George VA Medical Center
Asheville, North Carolina, 28805, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin 10mg daily
What this could lead to
If successful, this could point toward a way to slow or prevent prediabetes from turning into diabetes, and possibly reduce heart and kidney risks.
What could go wrong
This is a very early, small pilot study focused on feasibility, not on proving the drug works. Results may not apply to the general population, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.